Request ConsultationArgenx has halted its Phase 3 UNITY trial of efgartigimod for Sjogrens disease after an interim analysis indicated a low likelihood of success. The decision highlights the challenges of developing targeted autoimmune treatments and designing clinical trials that demonstrate meaningful patient benefits.
A Clinical Holdup That Highlights the Complexity of Autoimmune Diseases
Even with advances in understanding the immune system, drug companies still find it hard to develop effective treatments for autoimmune diseases. On October 8, 2026, Argenx announced it would stop its Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren’s disease.
The announcement was a setback for Argenx’s plans to use its known immunology medicine for another disease. Investors reacted negatively, causing the company’s shares to drop sharply as they reconsidered the chance of a new use in the biotechnology sector. It highlights the scientific uncertainty in turning promising immune-targeting ideas into treatments that actually improve patients’ health.
Sjögren’s disease is a long-lasting autoimmune condition that can cause dry eyes, dry mouth, tiredness, joint pain, and problems in organs beyond the glands that produce moisture. Symptoms and the disease’s biology differ a lot between patients, making it hard to develop treatments. The researchers have found several immune system pathways connected to the disease; finding a treatment that works well for many different patients is still difficult.
Importantly, Argenx stopped the UNITY study because it seemed unlikely to succeed, not because of new safety issues. The company said the safety results matched what was already known about efgartigimod and no new safety concerns appeared.
What Happened in Argenx’s Phase 3 UNITY Study?
The UNITY trial was designed to assess the efficacy, safety, and tolerability of subcutaneous efgartigimod in adults with moderate-to-severe primary Sjögren’s disease. Researchers used a randomized, double-blind, placebo-controlled, multicenter design to compare treatment outcomes and minimize potential bias.
The main goal was to see how much the overall disease activity changed after 48 weeks, measured by the clinical EULAR Sjögren’s Syndrome Disease Activity Index (clinESSDAI). Participants received either efgartigimod or placebo in addition to their usual stable treatments. Secondary measures included low disease activity, treatment response, symptoms reported by patients, safety, and treatment tolerability.
Following the initial review, an independent data monitoring committee advised halting the study because it was unlikely to succeed. In the field of clinical research, a futility check examines whether the trial still has a good opportunity of achieving its primary objective; if the evidence indicates that success is unlikely, then it is possible to save money and keep the participants from receiving unnecessary treatment.
The decision does not automatically mean that efgartigimod lacks biological activity in every patient or cannot work in other autoimmune conditions. Rather, it indicates that, under the conditions in which it was conducted, the UNITY study was unlikely to meet its specified primary endpoint.
Understanding Sjögren’s Disease and Its Unmet Medical Requirements
Sjögren’s disease is caused by the immune system wrongly attacking the body's own tissues, especially the exocrine glands which produce tears and saliva. The decreased production of moisture may result in continuous eye irritation, difficulty in swallowing dry foods, oral discomfort, and an increased risk of dental complications.
Many patients suffer from fatigue, have muscle aches and joint pain, and this can interfere with their everyday lives. In some cases, the condition leads to complications involving the skin, the lungs, the kidneys, the blood vessels, or the nervous system. Symptoms can be mild or severe, and the disease can progress in different ways in different people.
This variation creates a big challenge for drug developers. A therapy targeting one immune pathway might help patients whose disease depends on that pathway but have little effect on others whose symptoms come from different causes. Because of this, a treatment that seems promising in a small study might not show consistent benefits in a larger trial.
Current management usually involves providing symptom relief and treating specific complications when needed. Artificial tears, saliva replacements, oral care, and other supportive measures can improve a patient's quality of life.
The necessity for disease-modifying treatments remains important. Pharmaceutical companies are studying targeted antibodies, medicines that adjust the immune system, and other methods aimed at the biological processes behind autoimmune activity. The challenge is figuring out which targets are most important, which patients will respond, and how to measure treatment benefits accurately.
Why Efgartigimod Looked Like a Promising Candidate
Efgartigimod is designed to inhibit the neonatal Fc receptor (FcRn). Normally, this receptor protects immunoglobulin G (IgG) antibodies from breaking down, so they stay in the body longer. By blocking FcRn, efgartigimod helps the body break down IgG antibodies faster, including harmful autoantibodies involved in some autoimmune diseases.
This method offers a focused way to lower immune activity caused by antibodies. Instead of using broad immune suppression, the treatment targets how long a specific type of antibody stays in the body.
Efgartigimod is approved for other autoimmune conditions, including generalized myasthenia gravis. In applicable markets, its subcutaneous formulation, marketed as Vyvgart Hytrulo, is approved for chronic inflammatory demyelinating polyneuropathy. These clinical achievements have helped make the medicine a crucial part of Argenx’s immunology portfolio.
The reason the drug was studied in connection with Sjögren’s disease was in part due to the role that autoantibodies play in autoimmune processes. The researchers wanted to find out if decreasing the amount of IgG antibodies in the blood could improve the overall disease activity and patient outcomes.
However, just because autoantibodies are present does not mean that lowering antibodies alone will control all aspects of the disease. Sjögren’s disease involves many interacting immune pathways, and the causes of gland damage, tiredness, inflammation, and other complications may not all respond the same way to one treatment.
The UNITY result shows that a known treatment method working in one disease cannot be assumed to work the same in another. Each new use needs its own clinical proof that the treatment brings real benefits to the patients it is meant for.
Why Developing Drugs for Autoimmune Diseases Remains Challenging
Autoimmune diseases are biologically complex because the immune system consists of interconnected cells, signals, antibodies, and inflammation. Although focusing on one aspect may affect disease activity, other processes can still cause symptoms or tissue damage.
Differences between patients are one of the biggest challenges. Even with the same diagnosis, two people may have different disease severity, immune system features, affected organs, and responses to treatment. When these differences are mixed in one trial group, it can be harder to see the average treatment effect.
Another difficulty is the link between biological activity and actual benefit to patients. A drug may have an effect on its intended target without being sufficient to improve symptoms or the disease. While it is useful for drug developers to demonstrate that a drug reaches its target, this does not substitute for proof that it is of benefit to patients.
The fact that autoimmune diseases tend to follow a natural course also makes research more difficult. The symptoms may increase or decrease, and patients can get better or worse no matter what treatment is being tested. Moreover, other drugs and kinds of care can affect results, so researchers have to separate out the contribution of the medicine from the effects of other factors.
A few issues are especially important in autoimmune clinical research:
- Biological Variation: Patients may have different immune mechanisms despite sharing the same diagnosis.
- Endpoint Selection: Clinical measures must capture changes that are meaningful to patients and relevant to the disease.
- Treatment Time: Researchers may require extended follow-up to assess sustained advantages and disease progression.
- Safety Considerations: Medicines must establish an acceptable balance between potential benefits and risks
- Development Costs: Large, long-duration trials require substantial investment and careful operational planning.
For this reason, even when laboratory studies show promising results and early-stage trials are encouraging, success in Phase 3 cannot be guaranteed. Even though late-stage trials provide more definite evidence, they may show faults in the assumptions regarding a treatment's effectiveness.
The Role of Clinical Trial Design and Endpoint Selection
Designing clinical trials is momentous when testing treatments for varied diseases like Sjögren’s. Researchers must pick the right patients, decide on meaningful goals, set an appropriate treatment time, and consider other treatments and natural differences in results.
In UNITY, the main endpoint was the change in systemic disease activity by Week 48 as assessed with clinESSDAI. This measure looks at the systemic manifestations and provides a structured evaluation of disease activity beyond symptoms like dry eyes and dry mouth.
A medicine might improve some symptoms or change an immune marker without enough change in the main goal. If the effect is small or patient responses vary broadly, the difference between the treatment and placebo groups may fall short of the threshold for success.
Researchers should also think about whether participants have similar biological traits that might affect how they respond to the treatment. Recruiting many different patients can make a study more like real-world practice but can add a lot of variation. Choosing patients more carefully can make it easier to detect a treatment effect in a specific group, but the results might not apply to everyone.
Choosing the right goals is another challenge. A score measuring overall disease activity, a symptom questionnaire, and a lab biomarker each capture different parts of the condition. Because a treatment might affect one dimension more than others, consider all the evidence instead of focusing on a single result.
The discontinuation of UNITY does not identify which specific design factor explains the outcome. A detailed analysis of the data will be needed to determine what the trial reveals about the treatment, the enrolled population, and the biological mechanisms involved.
What a Futility Decision Means for Pharmaceutical Research
Futility analyses are an important part of modern clinical research. They help researchers decide if a trial is likely to meet its primary objective before all participants finish the study. Independent monitoring groups review the growing evidence and may suggest stopping the trial if success seems unlikely.
These decisions conserve research resources and could lessen the unnecessary risks for the participants. It would be wasted time and money to continue a study which is unlikely to answer its primary question without gaining sufficient scientific value.
Researchers can still study treatment use, patient traits, biomarkers, secondary goals, and response differences. These analyses can help form ideas, but any suggested group that responds to treatment will need proper confirmation.
For Argenx, the main goal is to understand why the UNITY study was unlikely to reach its main goal. For the broader research community, the results may offer a chance to rethink ideas about the role of IgG antibodies in Sjögren’s disease and how much blocking FcRn can affect its symptoms.
The value of this process depends on our ability to explain the results clearly. A failed trial should not be dismissed as meaningless or used to draw conclusions unsupported by the data. Instead, it should clarify what was tested and what remains uncertain.
Financial and Strategic Implications for Argenx
If UNITY is stopped, there will be a loss of an opportunity to expand the range of diseases for which Vyvgart Hytrulo has been approved. For drug companies, using an existing medicine to treat more diseases can lead to a wider market, provide additional sources of income, and help to ensure long-term growth.
The trial offered Argenx a chance to play a bigger role in rheumatology and Sjögren’s disease treatment. Its stopping changed expectations for future development and business potential. The sharp drop in share price after the news showed investors rethinking those expectations.
Biotech company values often depend on clinical milestones because expected future income partly relies on whether new products work and get approval. If a late-stage trial fails, analysts may change sales predictions, development plans, and estimates of the company’s future growth.
However, this setback should be seen in light of Argenx’s current products and wider development pipeline. The result of one clinical program does not determine how all other parts of the company’s portfolio will do.
On the same day, Argenx also shared positive mid-stage results for FB102 in celiac disease and said the program would move to late-stage development. FB102 is a different experimental medicine, so its results do not affect the UNITY outcome. They do, however, show how biotechnology companies can see contrasting results across various programs.
For investors, the main questions are whether current product income will endure, how compelling the evidence is for other drug candidates, and whether the company can manage clinical and business risks. For Argenx, the challenge is to learn from the Sjögren’s result while continuing to invest prudently in its remaining development opportunities.
Could Precision Medicine Advance Future Sjögren’s Research?
Precision medicine may help researchers consider the biological differences that affect Sjögren’s disease treatment. Rather than assuming the same causes affect every patient, researchers can study whether certain immune system features match specific symptoms or treatment responses.
biomarker is helpful only if its importance for patients has been shown. Researchers must find out if it reliably predicts how patients respond to treatment, shows real disease activity, or helps make better care decisions.
Future studies could check biomarkers earlier in development and see if treatment effects differ among well-defined patient groups. They could also combine overall disease activity scores with patient-reported symptoms to provide a fuller view of treatment benefits.
They will not eliminate the complexity of autoimmune diseases but might assist in selecting patients more effectively, help to focus research questions, and enable clinical studies to test targeted treatments more efficiently.
Future Outlook Building Better Evidence for Autoimmune Treatments
Future progress in developing drugs for autoimmune diseases will depend on stronger connections between disease biology, patient selection, clinical trial design, and meaningful outcomes. The setback reinforces the importance of evaluating these factors together rather than assuming a promising molecular target will automatically lead to clinical success.
Improved disease classification could help researchers understand differences between patients. Established biomarkers might enable more informed decisions regarding treatment. Setting well-chosen clinical objectives will ensure that the studies measure improvements that are important to patients, and effective trial monitoring will allow the teams to make adjustments as new evidence becomes available.
Drug companies have to balance the need for new ideas with careful control of their funds. Conducting a range of research projects can lessen the company's reliance on a single program, but each candidate still involves both scientific and business risks. Clear communication is also important, since investors, doctors, and patients all need to distinguish between proven results and early-stage ideas.
For Argenx the next aim is to complete the UNITY analysis and work out what the results mean for future research. Broadly speaking, however, the trial demonstrates that targeted immunology must continue to be studied, thoroughly understood, and there must be a readiness to reconsider scientific ideas when clinical evidence is scarce.
Conclusion
The fact that Argenx has decided to discontinue the Phase 3 UNITY trial represents a blow to the efforts to find new treatments for Sjögren’s disease. The interim analysis indicated that efgartigimod was probably not going to achieve the study's primary endpoint, and the safety results reported were in keeping with the drug's known profile.
This outcome shows that developing autoimmune drugs requires more than a good theory or success in another disease. Researchers must show real clinical benefits in the specific disease and patient group being studied.
For Argenx, the choice eliminates a possible avenue for the development of Vyvgart Hytrulo for use in Sjögren’s disease and highlights the significance of evidence-based portfolio management. For the pharmaceutical industry, the decision stresses the importance of improving disease characterization, patient selection, endpoint design, and the interpretation of clinical outcomes.
The trial's end does not mean progress in research into Sjögren’s disease has stopped. A careful examination of the results could help to pinpoint unanswered questions and assist in directing future studies. Ultimately, the success of developing drugs for autoimmune diseases will depend on converting scientific insights into safe and effective treatments that actually help patients.
About the Authors
Aditi Shivarkar
Aditi, Vice President at Precedence Research, brings over 15 years of expertise at the intersection of technology, innovation, and strategic market intelligence. A visionary leader, she excels in transforming complex data into actionable insights that empower businesses to thrive in dynamic markets. Her leadership combines analytical precision with forward-thinking strategy, driving measurable growth, competitive advantage, and lasting impact across industries.
Aman Singh
Aman Singh with over 13 years of progressive expertise at the intersection of technology, innovation, and strategic market intelligence, Aman Singh stands as a leading authority in global research and consulting. Renowned for his ability to decode complex technological transformations, he provides forward-looking insights that drive strategic decision-making. At Precedence Research, Aman leads a global team of analysts, fostering a culture of research excellence, analytical precision, and visionary thinking.
Piyush Pawar
Piyush Pawar brings over a decade of experience as Senior Manager, Sales & Business Growth, acting as the essential liaison between clients and our research authors. He translates sophisticated insights into practical strategies, ensuring client objectives are met with precision. Piyush’s expertise in market dynamics, relationship management, and strategic execution enables organizations to leverage intelligence effectively, achieving operational excellence, innovation, and sustained growth.